No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Li, Jonathan Z, Sax, Paul E, Marconi, Vincent C, Fajnzylber, Jesse, Berzins, Baiba, Nyaku, Amesika N, Fichtenbaum, Carl J, Wilkin, Timothy, Benson, Constance A, Koletar, Susan L, Lorenzo-Redondo, Ramon, Taiwo, Babafemi O
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419983/
https://ncbi.nlm.nih.gov/pubmed/30895201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz056
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados